default author photo

Xianping Lu

Chipscreen Biosciences Ltd

Shenzhen

China

SCHOLARLY PAPERS

2

DOWNLOADS

169

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Efficacy and Safety of the Peroxisome Proliferator-Activated Receptor Pan-Agonist Chiglitazar in Patients with Type 2 Diabetes (CMAP): A 24 Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial

Number of pages: 100 Posted: 21 Aug 2019
Peking University - Department of Endocrinology and Metabolism, Southern Medical University - Chenzhou No.1 People's Hospital, Tangshan Gongren Hospital, Xuzhou Medical University, Harrison International Peace Hospital, Qingdao University - Affiliated Hospital, China Three Gorges University (CTGU) - College of Medical Science, Jilin University (JLU) - Second Hospital, Jiangsu Province Hospital, China Meitan General Hospital, Chongqing University, Chongqing Medical University - Department of Endocrinology, Hebei Medical University, Tianjin Medical University - General Hospital, Government of the People's Republic of China - 306th Hospital, Baogang Hospital of Inner Mongolia, Cangzhou Central Hospital, Fudan University - Zhongshan Hospital, Sichuan University, Government of the People's Republic of China - Air Force Medical University, Shanghai Jiao Tong University (SJTU) - Xinhua Hospital, Central South University - Key Laboratory of Diabetes Immunology, Peking University, Central South University - Second Xiangya Hospital, Xiamen University - First Affiliated Hospital, Wuhan University - Zhongnan Hospital, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd and Shanghai Jiao Tong University (SJTU) - Department of Endocrinology and Metabolism
Downloads 94 (720,278)

Abstract:

Loading...

2.

Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial

Number of pages: 90 Posted: 05 Feb 2019
Chinese PLA General Hospital - The Fifth Medical Center, Department of Medical Oncology, Jilin University (JLU) - First Affiliated Hospital, Fudan University - Shanghai Cancer Center (FUSCC), Harbin Medical University - Cancer Hospital, Liaoning Cancer Hospital & Institute - Department of Medical Oncology, Zhengzhou University - Henan Cancer Hospital, Sun Yat-Sen University (SYSU) Cancer Center - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Jiangsu Province People's Hospital, Tumour Hospital of Hebei Province, Tianjin Medical University, Jilin Cancer Hospital, Anhui Medical University - Department of Medical Oncology, Shandong University - Jinan Central Hospital, Third Hospital of Nanchang, Beijing Cancer Hospital, Anhui Medical University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Institute of Cancer Research, Zhejiang Cancer Hospital - Department of Medical Oncology, Peking University - Shenzhen Hospital, Fudan University, Zhongshan Hospital, Department of Oncology, Cangzhou Central Hospital, Northwestern University - Feinberg School of Medicine, Chipscreen Biosciences Ltd and Chipscreen Biosciences Ltd
Downloads 75 (837,727)

Abstract:

Loading...

Chidamide; Histone deacetylase inhibitor; Exemestane; Hormonereceptor- positive; Advanced breast cancer; Phase 3 trial